Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACYW versus Menveo in healthy children aged 2 to 9 years
2018-001471-20Phase 3
- Sponsor
- Sanofi
- Start
- Jul 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Meningococcal conjugate vaccine quadrivalent and meningococcal A conjugate vaccine in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoint: Antibody titers against meningococcal serogroups A, C, Y, and W.
02
Drugs
Meningococcal conjugate vaccine quadrivalentmeningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2018-001471-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001471-20.